. Death from localised prostate cancer is uncommon partly because it tends to affect elderly men and partly because of its slow growth (Blute et al., 1986; George, 1988) . There is a need to identify those tumours that are likely to progress sufficiently to become symptomatic.
Carcinoma of the prostate is one of the commonest tumours in men (Hutchinson, 1981) . Latent prostate cancer occurs in 5% of men aged 40-49 years, rising to 40% or more of men aged over 80 years (Wynder et al., 1971; Holund, 1980) . Despite a similar incidence of latent disease in different countries, clinically apparent disease is variable. The highest incidence is seen in US blacks (95.7 cases per 105 males per annum) and the lowest in the Far East (Zaridze & Boyle, 1987) . Mortality varies from 24 deaths per 105 males per year in US blacks to 12 deaths per 105 males per year in England and Wales (Zaridze & Boyle, 1987) . Death from localised prostate cancer is uncommon partly because it tends to affect elderly men and partly because of its slow growth (Blute et al., 1986; George, 1988) . There is a need to identify those tumours that are likely to progress sufficiently to become symptomatic.
The retinoblastoma susceptibility gene (RB1) was first localised to chromosome 13ql4.1 by cytogenetic studies (Yunis & Ramsay, 1978) . The gene was cloned by Friend et al. (1986) and was the first tumour-suppressor gene to be identified (Benedict et al., 1990) . Osteosarcomas occur with an increased incidence in surviving adults with hereditary retinoblastoma and show the same mechanism of RB1 loss as in retinoblastoma (Friend et al., 1986) . Loss of heterozygosity (LOH) per se does not indicate that inactivation of a gene at that locus is important in the malignant process: a 'background' LOH rate of up to 15% was noted in nearly two-thirds of polymorphic markers studied in colorectal cancer (Vogelstein et al., 1989) . Higher rates of allelic loss are more suggestive of a causal role, especially when inactivating mutations of the gene are also found. Both allele loss and RB1 mutations have been documented in a substantial proportion of small-cell lung cancers (Harbour et al., 1988) , sarcomas (Wunder et al., 1991) , breast cancers (Lee et al., 1988; T'Ang et al., 1988; Varley et al., 1989) and bladder cancer (Yandell et al., 1989; Cairns et al., 1991) and in other various tumours. The protein product of the RB1 gene (pRB) has a pivotal role in the control of the cell cycle, blocking entry into the S-phase when dephosphorylated (Hinds el al., 1992 (Bookstein et al., 1990b) . A preliminary study within our unit, based on small numbers, showed LOH of the RB1 locus in six out of nine informative prostate cancer cases (Phillips et al., 1994 (Feinberg & Vogelstein, 1984 (Greger et al., 1989) .
LOH using polymerase chain reaction (PCR) Primers to RB1 introns 17 (Greenwald et al., 1992) and 20 (Onadim et al., 1992) fragments loaded. Fragments were separated by electrophoresis in 6% non-denaturing polyacrylamide gels incorporating 10% glycerol (similar to those used for single-strand conformation polymorphism analysis). Gels were run at low power so that no heating occurred and the DNA strands did not separate. After electrophoresis the gels were dried and applied to autoradiographic film. Results were assessed visually and then checked using densitometry.
All tumour and BPH samples were hybridised with probes p123ml.8 and p68RS2.0 and amplified using PCR to intron 20. Patients who were non-informative to all of these three loci, were informative but showed no loss of heterozygosity, or were cases of special interest were additionally examined using PCR to intron 17. Cases showing deletions had the RFLP and/or PCR reactions repeated to confirm the result. Particular care was taken to confirm results in those patients in whom just one locus showed a deletion. All cases of LOH were confirmed using densitometry.
Immunohistochemistry
Nine patients with cancer and four with BPH were selected at random, and paraffin sections cut at 3 lsm from their original histology blocks. The streptavidin-biotin complex method was used to demonstrate Rb protein. Sections were mounted on Vectabond (Vector laboratories) treated glass slides, dewaxed in xylene, then rehydrated through graded alcohols to water. The sections were then placed in a citrate buffer bath (pH 6) and microwaved (750 W) for 30 min (Norton, 1993) . They were then rinsed with water, bathed in 1% hydrogen peroxide in methanol, rinsed in water and incubated with the mouse monoclonal antibody NCL-RB (NovoCastra Laboratories), diluted to optimum with 0.01 M PBS. After 1 h the sections were washed in 0.01 M PBS and the primary antiserum labelled with streptavidin-biotin complex-horseradish peroxidase (Duet Kit; K492, Dako). The horseradish peroxidase was visualised with 3,3'-diaminobenzidine tetrahydrochloride as a substrate and the nuclei counterstained for interpretation (Cattoretti et al., 1992) . Immunohistochemical staining showed pRB to be within the cell nucleus. In common with another immunohistochemical study of pRB using a different antibody (RBl-Ab20; Varley et al., 1989) T2MO (n = 6), T2M1 (n = 5), T3MO (n = 6), T3M1 (n = 12), T4MO (n = 5 and T4M1 (n = 8). The tumours were graded as well (n = 5), moderately (n = 14) and poorly differentiated (n = 24).
Loss of heterozygosity in cancer tissue
Samples from 40 of 43 cancer patients were informative to one or more DNA probes/PCR sequences (Table II) . Overall 24 (60%) out of 40 tumours showed loss of heterozygosity at one or more loci examined. Of these 24 patients, 4 (27%) out of 15 informative cases showed loss with probe pl23ml.8, 11 (48%) out of 23 informative cases showed loss with probe p68RS2.0 and 13 (54%) out of 24 informative cases showed loss with PCR to RB1 intron 20 (Figure 1 ).
Twelve out of 24 cancers showing LOH exhibited a deletion at the only intron at which the case was informative. Seven cases showing LOH had losses at both of the two informative introns for that patient. The remaining five patients showed interstitial loss with preservation of part of the gene. Loss of the 5' region with preservation of the 3' end was shown by one tumour (number 10). Loss of the 3' region with preservation of the 5' end was found in three tumours. Loss of intron 17 with preservation of the flanking 5' and 3' ends was seen in one case (number 39). Examination of gel loading and comparison with the allele strength in informative cases gave no indication of any chromsomal duplications. One tumour (number 13) showed a rearrangement with novel allele formation on PCR to intron 20 (Figure 2 ). This PCR reaction was repeated with consistent results. All of the tumour/blood DNA samples have been examined at 22 different chromosomal loci (unpublished data), mostly VNTR polymorphisms. None of them, including tumour number 13, showed any disparity between the allele size displayed by tumour or blood DNA at these other loci, indicating that there had been no error in sample labelling during paired normal and tumour DNA extraction. Prostate cancer is a diffusely infiltrating tumour, and the densitometry readings were used to assess the degree of background benign tissue contamination. Of those tumours showing LOH, 15 had a 70% or greater reduction in the signal strength of the deleted allele, six showed a 50-69% reduction and three showed a 30-40% reduction in the deleted allele. The last three cancers had a high precentage of benign tissue contamination despite tumour microdissection.
Loss of heterozygosity in BPH tissue
Of the nine informative benign (BPH) prostates, one showed LOH to intron 1 (BamHI polymorphism) using probe p123ml.8 and intron 17 (XbaI polymorphism) as revealed by PCR ( Figure Id) . This tissue showed retention of the 3' locus within intron 17 as revealed by probe p68RS2.0. Intron 17 is large and the XbaI and VNTR polymorphism are 20kb apart (Wiggs et al., 1988) . Densitometry showed a greater than 60% reduction in the size of the deleted allele from the BPH tissue when compared with its counterpart derived from blood.
Examination of the two loci showing loss in this patient was repeated five times with consistent results. All of the tissue resected from this 79-year-old patient (E) showed benign hyperplasia with both epithelial and stromal elements. There was no evidence of malignancy on histological examination, including the frozen section material used for DNA extraction. Despite the benign histology, this patient had a nodular prostate on rectal examination. A bone scan was performed, which was normal, and the prostate-specific antigen (PSA) was marginally elevated (20 ng l-1). The nodularity of the prostate and the elevated PSA strongly suggest an occult prostatic cancer. After reviewing the overall clinical picture in this patient, further biopsy of the prostate gland was not considered to be ethical, but he remains under careful clinical follow-up.
Loss of heterozygosity vs stage and grade RBl loss was similar between different stages and grades of tumour. LOH within tumours confined to the prostate (TI and T2) was 60% (6/10); loss within those with extracapsular spread of tumour (T3 and T4) was also 60% (18/30). The MO tumours showed LOH in 56% (9/16) cases; those with bone metastases (MI) showed loss in 62% (15/24) cases. Welldifferentiated tumours showed loss in 80% (4/5) cases, moderately differentiated tumours showed loss in 71% (10/ 14) of cases and the poorly differentiated tumours showed LOH in 48% (10/21) of cases. There was no correlation between loss of RB1 and the grade or stage of tumour.
Immunohistochemistry
Of the nine tumour patients examined, four had shown a deletion of RB1, four were informative without LOH and one was non informative to all introns examined. Seven showed complete loss of pRB and two showed marked reduction of tumour nuclear staining (Table III) . Seven of the tumours also contained areas of BPH within the sections examined, and a higher percentage and a greater intensity of nuclear staining was seen in the BPH cells than in adjacent tumour cell nuclei (Figure 3 ). All four cases with BPH alone showed greater staining than the tumours. There was no relationship between the proportion of nuclei showing loss of pRB staining and the reduction of the allele signal (as assessed by densitometry) in those showing LOH. This may have been because the material used for immunohistochemistry was from different prostatic curettings to those used for microdissection and DNA extraction.
Discussion
Loss of heterozygosity within the RBl gene was identified in 60% of prostate cancers, which is higher than has previously been reported (Carter et al., 1990; Macoska et al., 1992;  Sarkar et al. (1992) looked for deletions within the DNA of the RBl promoter region and within exon 21 mRNA. They found an abnormal short-sized mRNA transcript of RB1 exon 21 extracted from a pure population of cells in tissue culture (cell line DU 145), but not in their seven cancer cases. No deletions within the promoter region were detected. The techniques used, however, would not have detected deletions lying outside the two loci studied or deletions of the whole of the promoter or exon 21 loci. If the whole of these loci had have been lost in the cases they studied, DNA or mRNA from benign tissue contamination would have been amplified to give a normal-sized band. Macoska et al. (1992) used only a single chromosome 13q marker and accepted a high degree of benign tissue contamination of tumour DNA. They found no losses in 19 informative cases, possibly because of benign DNA contamination and the fact that the probe used would not detect the small intragenic deletions that we and other workers have found within RB1.
The RBl gene consists of 27 exons spread over 200 kb of genomic DNA (Hong et al., 1989) , which poses problems for the detection of small deletions. The cancer samples in this study were informative at one or more loci studied in 93% (40/43) -of cases. Combining the results of all four loci gave a higher rate of allelic loss than the use of any single locus alone. There were 12 cases in which the only informative locus showed the allele loss. Small interstitial deletions of the RB1 gene have been widely reported in a number of different tumours, including bone and soft-tissue sarcomas (Wunder et al., 1991) , breast cancer (T'Ang et al., 1988) and bladder cancer (Cairns et al., 1991) .
In seven of the nine tumours immunohistochemistry showed pRB loss in 95-99% of tumour nuclei. In the other two cases loss was seen in 75-94% of tumour nuclei. The presence of some pRB nuclear staining could be explained by the presence of mutant pRB which may be functionally inactive or by the retention a small clone of cells without pRB loss. This may suggest that loss of RBI, though early, is not the initiating event in carcinogenesis (Benedict et al., 1990) . Another possibility is that there is limited expression of the retained RBI allele (possibly mutant), subject to activity of controlling genes.
One patient with BPH showed loss of heterozygosity of RB1, which may represent a premalignant field change occurring within the gland. de Vere White et al. (1992) noted abnormal RBI mRNA expression in 1 of 13 benign prostates. Our case may be similar to this, though whether alteration of RB1 is representative of a premalignant change or has a role in prostatic adenoma or hyperplasia is unclear.
This study has shown that loss of RBl gene is a frequent and possibly early event in prostatic tumorigenesis 
